Cost-Effectiveness Analysis of Erythropoietin in Anemia Therapy Strategies for Chronic Kidney Disease Patients Undergoing Hemodialysis: A Systematic Review

Authors

  • Rosi Ami Sari Sekolah Tinggi Ilmu Farmasi Riau (STIFAR-RIAU)
  • Seftika Sari Sekolah Tinggi Ilmu Farmasi Riau, Jl. Kamboja, Simpang Baru-Panam-Pekanbaru, 28293, Indonesia
  • Dwi Endarti Sekolah Tinggi Ilmu Farmasi Riau, Jl. Kamboja, Simpang Baru-Panam-Pekanbaru, 28293, Indonesia
  • Neni Frimayanti Sekolah Tinggi Ilmu Farmasi Riau, Jl. Kamboja, Simpang Baru-Panam-Pekanbaru, 28293, Indonesia

Keywords:

Cost effectiveness analysis, Anemia, Chronic Kidney Disease, Erythropoietin Hemodialysis

Abstract

Chronic kidney disease is a significant health issue, with increasing case numbers leading to higher treatment costs. This condition causes decreased kidney function and can result in anemia due to impaired red blood cell production. This study aims to analyze the cost-effectiveness of anemia treatment using Erythropoietin, either as a single therapy or in combination, for patients with chronic kidney failure undergoing hemodialysis. The methods employed include conducting a systematic review to identify problems, establish inclusion and exclusion criteria, and search various databases for relevant studies. The results show that cost-effectiveness varies depending on the Hemoglobin target and the type of Erythropoietin used. In conclusion, setting an appropriate Hemoglobin target and selecting the correct type of Erythropoietin are crucial for effective anemia treatment. This systematic review recommends a Hemoglobin target of >10–11 g/dL and the use of Erythropoietin is adjusted to the patient's condition so that the choice is more cost effective.

Downloads

Download data is not yet available.

References

Ahsan, M.N. et al. (2021) ‘Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study’, Journal of Community Hospital Internal Medicine Perspectives, 11(6), pp. 782–786. Available at: https://doi.org/10.1080/20009666.2021.1983980.
AlKharboush, H. et al. (2020) ‘The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients’, Cureus, 12(12). Available at: https://doi.org/10.7759/cureus.11895.
Babitt, J.L. and Lin, H.Y. (2012) ‘Mechanisms of anemia in CKD’, Journal of the American Society of Nephrology, 23(10), pp. 1631–1634. Available at: https://doi.org/10.1681/ASN.2011111078.
Ferguson, T. et al. (2015) ‘The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: A systematic review’, American Journal of Nephrology, 41(2), pp. 89–97. Available at: https://doi.org/10.1159/000375541.
Hanna, R.M., Streja, E. and Kalantar-Zadeh, K. (2021) ‘Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin’, Advances in Therapy, 38(1), pp. 52–75. Available at: https://doi.org/10.1007/s12325-020-01524-6.
Hustrini, N.M., Susalit, E. and Rotmans, J. (2022) ‘Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018’, Journal of Global Health, 12, pp. 1–10. Available at: https://doi.org/10.7189/jogh.12.04071.
Kartikawati, N.D., Andayani, T.M. and Endarti, D. (2022) ‘Cost Effectiveness Analysis (CEA) Strategi Terapi Anemia pada Pasien Penyakit Ginjal Kronis’, Jurnal Manajemen dan Pelayanan Farmasi(Journal of Management and Pharmacy Practice), 12(3), p. 164. Available at: https://doi.org/10.22146/jmpf.72614.
KDIGO (2024) ‘KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease’, Kidney International, 105(4), p. A1. Available at: https://doi.org/10.1016/s0085-2538(24)00110-8.
KEMENKES (2023) ‘Keputusan Menteri Kesehatan RI Tentang Pedomal Tata Laksana Gagal Ginjal Kronik’, pp. 1–289. Available at: jdih.kemkes.go.id.
Nguyen, T.D. et al. (2018) ‘Cost-Effectiveness Analysis Of Anemia Treatment Among Chronic Kidney Disease Patients At Kien Giang General Hospital’, Eurasian Journal of Analytical Chemistry, pp. 263–270. Available at: issn: 1306-3057.
Nurtandhee, M. (2023) ‘Estimasi Biaya Pelayanan Kesehatan sebagai Upaya Pencegahan Defisit Dana Jaminan Sosial untuk Penyakit Gagal Ginjal’, Jurnal Jaminan Kesehatan Nasional, 3(2), pp. 84–101. Available at: https://doi.org/10.53756/jjkn.v3i2.104.
Purnomo, L.S., Dewi, L.V.I. and Hanifah, I.R. (2024) ‘Analisis efektivitas biaya terapi anemia pada pasien hemodialisis GGK di RS X’, Health Sciences and Pharmacy Journal, 8(1), pp. 21–30. Available at: https://doi.org/10.32504/hspj.v8i1.995.
Ramatillah, D.L., Syarifah, N. and Khan, K.U. (2019) ‘Mortality among Chronic Kidney Failure Patients Who Have died in Last 2 years and the Correlation with Erythropoietin and / or Blood Transfusion as an Anemia Therapy in Jakarta , Indonesia ’ s’, Dialysis and Transplantation Open Access, 2(2).
Romagnani, P. et al. (2017) ‘Chronic kidney disease’, Nature Reviews Disease Primers, 3. Available at: https://doi.org/10.1038/nrdp.2017.88.
Sari, N., Srikartika, V. and Intannia, D. (2015) ‘Profil dan Evaluasi Terapi Anemia pada Pasien Gagal Ginjal Kronik yang Menjalani Hemodialisa di BLUD RS Ratu Zalecha Martapura Periode Juli-Oktober 2014’, Jurnal Pharmascience, 2(1), pp. 65–71.
Soliman, A.E. et al. (2024) ‘Short versus long-acting erythropoiesis-stimulating agents for anemia management in Egyptian hemodialysis patients’, Qatar Medical Journal, 2024(1), pp. 1–12. Available at: https://doi.org/10.5339/qmj.2024.16.
Webster, A.C. et al. (2017) ‘Chronic Kidney Disease’, The Lancet, 389(10075), pp. 1238–1252. Available at: https://doi.org/10.1016/S0140-6736(16)32064-5.
Yarnoff, B.O. et al. (2016) ‘The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease’, American Journal of Kidney Diseases, 55(3), pp. 452–462. Available at: https://doi.org/10.1053/j.ajkd.2009.11.016.

Downloads

Published

2024-12-31

How to Cite

Sari, R. A., Sari, S., Endarti, D., & Frimayanti, N. (2024). Cost-Effectiveness Analysis of Erythropoietin in Anemia Therapy Strategies for Chronic Kidney Disease Patients Undergoing Hemodialysis: A Systematic Review. JOPS (Journal of Pharmacy and Science), 8(1), 124–132. Retrieved from https://jurnal.univrab.ac.id/index.php/jops/article/view/5274

Issue

Vol. 8 No. 1 (2024): Journal of Pharmacy and Science

Section

Articles

License

1. Copyright of all journal manuscripts is held by the JOPS (Journal Of Pharmacy and Science)

2. Formal legal provisions to access digital articles of electronic journal are subject to the provision of the Creative Commons Attribution-ShareAlike license (CC BY-NC-SA), which means that JOPS (Journal Of Pharmacy and Science) is rightful to keep, transfer media/format, manage in the form of databases, maintain, and publish articles.

3. Published manuscripts both printed and electronic are open access for educational, research, and library purposes. Additiponally, the editorial board is not responsible for any violations of copyright law.

Hasil gambar untuk by-nc-sa licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.